IP Library Granted Patent US 9,815,881
Granted Patent B2
US 9,815,881 · App. 13/756,063 · Granted Nov 14, 2017

Method of inducing labor or treating pre-eclampsia by administering relaxin analogs

Inventors: Jae-Il Park (Houston, TX); Sheau Yu Hsu (Menlo Park, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C07K14/64A61K38/2221A61K38/00A61K38/17C07K14/47
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,815,881
App. No.
13/756,063
Granted
Nov 14, 2017
Kind
B2
Abstract

Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.

Claims (11)

1. A method of treating preeclampsia, comprising administering to an individual an effective dose of a pharmaceutical formulation comprising a purified polypeptide analog of a mammalian relaxin 2 (RLN2) protein comprising an amino acid substitution at one or both of amino acid residues 16 and 17 to an amino acid other than the wild-type in the A chain, wherein the analog has increased activity for activation of the relaxin receptors LGR7 or LGR8 relative to the wild type protein; and a pharmaceutically acceptable excipient.

2. The method of claim 1 , wherein the polypeptide is a human RLN2 polypeptide comprising a substitution at residue 16 to an amino acid other than threonine.

3. The method of claim 1 , wherein the polypeptide is a human RLN2 polypeptide comprising a substitution at residue 17 to an amino acid other than lysine.

4. The method of claim 1 , wherein the amino acid at residue 16 or 17 is selected from alanine, glycine, isoleucine and leucine.

5. The method of claim 1 , wherein the polypeptide analog is covalently linked to a RLN2 B chain.

6. The method of claim 5 , wherein the RLN2 B chain has a wild-type amino acid sequence.

7. The method of claim 5 , wherein the RLN2 B chain is a variant of the wild-type RLN2 B chain amino acid sequence.

8. The method of claim 1 , wherein the A chain and the B chain are covalently linked to a relaxin C chain.

9. The method of claim 8 , wherein the C chain is a truncated C chain.

10. The method of claim 1 wherein the effective dose is from 0.05 to 500 μg/kg.

11. The method of claim 1 , wherein the effective dose is from 5 to 200 μg/kg.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2013
From: PARK, JAE-IL; HSU, SHEAU YU
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 031029/0606 →
CONFIRMATORY LICENSE Recorded Mar 8, 2013
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029942/0517 →
Continuity (3)
Continuation 12852373 · Aug 6, 2010
Provisional Application 61273951 · Aug 10, 2009
Related Publication 20130244938A1 · Sep 19, 2013